Workflow
Vertex(VRTX)
icon
Search documents
Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development
Zacks Investment Research· 2024-04-02 16:31
Vertex Pharmaceuticals (VRTX) initiated the late-stage portion of the phase II/III AMPLITUDE study evaluating inaxaplin (VX-147) in APOL1-mediated kidney disease (AMKD), a genetic disorder affecting kidney function.This phase III portion will evaluate a 45 mg oral dose of Vertex’s drug, on top of standard of care, in AMKD patients, compared with placebo. Management also expanded the study to include adolescents aged 10 and older with AMKD. Previously, the AMPLITUDE study only enrolled adults with the diseas ...
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Zacks Investment Research· 2024-04-01 22:56
In the latest market close, Vertex Pharmaceuticals (VRTX) reached $420.48, with a +0.59% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.2%. Elsewhere, the Dow saw a downswing of 0.6%, while the tech-heavy Nasdaq appreciated by 0.11%.Prior to today's trading, shares of the drugmaker had lost 3.41% over the past month. This has lagged the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32% in that time.The investment community will be c ...
1 Top Growth Stock to Buy and Hold Forever
The Motley Fool· 2024-03-31 13:15
Biotech giant Vertex Pharmaceuticals (VRTX 0.17%) has outperformed the S&P 500 in the past three, five, and 10 years. That's not a fluke: The drugmaker has been highly successful financially while displaying its incredible innovative abilities. Thankfully, it's not too late to invest in Vertex even with the market-beating returns it has provided in recent years.The company's underlying business remains as strong as ever -- strong enough that the stock is an excellent "forever" pick. Let's find out more.VRTX ...
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
Zacks Investment Research· 2024-03-22 17:11
Vertex Pharmaceuticals Incorporated (VRTX) announced that the FDA has cleared its investigational new drug application to begin clinical development of its pipeline candidate, VX-407, for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Vertex plans to begin a phase I study on VX-407 in ADPKD later this month.VX-407 is a first-in-class small molecule corrector that targets the underlying cause of this common inherited kidney disease, which leads to growth of several kidney-enlarging cy ...
Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Seeking Alpha· 2024-03-21 04:00
Solskin/DigitalVision via Getty Images Vertex Pharmaceuticals (NASDAQ:VRTX) is a promising biotechnology with solid financial results in 2023, a dominant Cystic fibrosis ("CF") franchise, and is on track to diversify its drug portfolio by launching five new products by 2028, which include its newest CF drug, a non-opioid pain management drug, and a therapy addressing Sickle Cell Disease and Beta-Thalassemia. Several of these solutions have the potential to produce blockbuster status. Investors were excited ...
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
Zacks Investment Research· 2024-03-18 22:56
The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $411.38, reflecting a +0.91% shift from the previouse trading day's closing. The stock's change was more than the S&P 500's daily gain of 0.63%. At the same time, the Dow added 0.2%, and the tech-heavy Nasdaq gained 0.82%.Prior to today's trading, shares of the drugmaker had lost 3.44% over the past month. This has lagged the Medical sector's gain of 0.91% and the S&P 500's gain of 1.76% in that time.The investment communit ...
Vertex Pharmaceuticals Incorporated (VRTX) Leerink Partners Global Biopharma Conference (Transcript)
2024-03-12 03:14
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Leerink Partners Global Biopharma Conference Call March 11, 2024 4:00 PM ET Company Participants Charlie Wagner - Executive Vice President & Chief Financial Officer David Altshuler - Chief Scientific Officer Conference Call Participants David Risinger - Leerink Partners David Risinger Good afternoon, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners [ph]. Two members of the Vertex leadership team; immediately to ...
Vertex Pharmaceuticals Incorporated (VRTX) Leerink Partners Global Biopharma Conference (Transcript)
Seeking Alpha· 2024-03-12 03:14
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Leerink Partners Global Biopharma Conference Call March 11, 2024 4:00 PM ET Company Participants Charlie Wagner - Executive Vice President & Chief Financial Officer David Altshuler - Chief Scientific Officer Conference Call Participants David Risinger - Leerink Partners David Risinger Good afternoon, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners [ph]. Two members of the Vertex leadership team; immediately to ...
Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 44th Annual Health Care Conference (Transcript)
2024-03-05 19:52
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) TD Cowen 44th Annual Health Care Conference Call March 5, 2024 10:30 AM ET Company Participants David Altshuler - Executive Vice President, Research and Chief Scientific Officer Charlie Wagner - Executive Vice President and Chief Financial Officer Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good morning, and welcome once again to TD Cowen’s 44th Annual Healthcare Conference. I am Phil Nadeau, one of the biotech analysts, and it’s my pleas ...
Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 44th Annual Health Care Conference (Transcript)
Seeking Alpha· 2024-03-05 19:52
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) TD Cowen 44th Annual Health Care Conference Call March 5, 2024 10:30 AM ET Company Participants David Altshuler - Executive Vice President, Research and Chief Scientific Officer Charlie Wagner - Executive Vice President and Chief Financial Officer Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good morning, and welcome once again to TD Cowen’s 44th Annual Healthcare Conference. I am Phil Nadeau, one of the biotech analysts, and it’s my pleas ...